c108617.htm - Generated by SEC Publisher for SEC Filing

 

 

 

 


 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549
 

________________

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

July 1, 2013

________________

 

        NOVO NORDISK A/S        
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]     

     Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]     

      No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 

 

 


 

 

logo.gif

 

 

Novo Nordisk A/S – Share repurchase programme

 

Bagsværd, Denmark, 1 July 2013 – On 3 May 2013, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14.0 billion to be executed during a 12-month period beginning 31 January 2013.

 

Under the programme initiated 3 May 2013, Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 6 May 2013 to 6 August 2013.

 

Since the announcement as of 24 June 2013, the following transactions have been made under the programme:

 

 

Number of shares

Average purchase price

Transaction value, DKK

Accumulated, last announcement

1,592,500

 

1,515,009,435

24 June 2013

57,000

856.53

48,822,444

25 June 2013

45,000

870.94

39,192,165

26 June 2013

50,000

884.23

44,211,405

27 June 2013

45,000

903.04

40,636,976

28 June 2013

50,000

894.43

44,721,260

Accumulated under the programme

1,839,500

 

1,732,593,684

 

With the transactions stated above, Novo Nordisk owns a total of 14,976,660 treasury shares, corresponding to 2.7% of the share capital. The total amount of shares in the company is 550,000,000 including treasury shares.

 

Novo Nordisk expects to repurchase B shares for an amount up to DKK 14.0 billion during a 12-month period beginning 31 January 2013. As of 28 June 2013, Novo Nordisk has

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

CVR no:

Investor Relations

2880 Bagsværd

+45 4444 8888

24 25 67 90

Denmark

Internet:

 

 

www.novonordisk.com

 

 

 

 

Company announcement No 47 / 2013

         

 

 


 

 

Page 2 of 2

 

repurchased a total of 7,451,310 B shares equal to a transaction value of DKK 7,235,305,119.

 

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 35,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.  

 

 

Further information

Media:

 

 

Anne Margrethe Hauge

+45 4442 3450

amhg@novonordisk.com

Ken Inchausti (US)

+1 609 514 8316

kiau@novonordisk.com  

 

 

 

Investors:

 

 

Kasper Roseeuw Poulsen

+45 4442 4303

krop@novonordisk.com

Frank Daniel Mersebach

+45 4442 0604

fdni@novonordisk.com

Lars Borup Jacobsen

+45 3075 3479

lbpj@novonordisk.com  

Jannick Lindegaard (US)

+1 609 786 4575

jlis@novonordisk.com

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

CVR no:

Investor Relations

2880 Bagsværd

+45 4444 8888

24 25 67 90

Denmark

Internet:

 

 

www.novonordisk.com

 

 

 

 

Company announcement No 47 / 2013

         

 

 

 


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: July 1, 2013

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer